57 results about "Beta globulins" patented technology

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i.e., a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i.e., a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment. The switch region and membrane exons of the invention may comprise a human gamma-2 constant region and the secreted constant region exons are from a human gamma-1 or a human gamma-4 constant region.

The invention provides a method for improving the gene targeting efficiency and a method for carrying out in-situ repair on the base on a beta-globulin gene locus. The method for improving the gene targeting efficiency comprises the following steps of: S10, determining a gene locus to undergo in-situ repair; and S20, introducing a CRISPR / Ca system to cleave editing lotus DNA to cause DNA damage and simultaneously providing a repair template segment. Based on the deficiency of existing gene modification, the gene modification efficiency, the timeliness and the modification quality are improved after single-stranded oligonucleotides (ss ODNs) and a small molecule compound participate in a CRISPR / Cas9 gene modification system.

The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and / or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.

The present invention provides methods for the quantification of human, human chimeric, humanized antibodies or fragments thereof without the use of target specific molecules. More specifically, the present invention relates to a quantitative assay comprising the step of blocking the non-specific binding sites of a capture agent with a blocking buffer comprising a non-human mammalian globulin such as bovine gamma globulin (BGG).

The invention discloses a method, primer, probe and kit for identifying various gene mutations or substance genetic typing. In one embodiment, the disease is pathogenic. In the other embodiment, the invention is applied to detection of multidrug-resistant Mycobacterium tuberculosis, hepatitis B virus, beta-globulin mutation, thrombophilia related mutation; or various sexually transmitted pathogens, consisting of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum, Herpes simplex virus 1 , Herpes simplex virus 2, Human papillomavirus type 6, and Human papillomavirus type 1.

The present invention provides methods, primers, probes, and kits for identifying gene mutation or material genotyping. In one embodiment, the materials are disease-causing agents. In another embodiment, the present invention is applied to detecting multidrug-resistant mycobacterium tuberculosis, hepatitis B virus, beta-globulin mutation, thrombosis-related mutations; or multiple sexually transmitted diseases causing agents, including but not limited to, trichomonas vaginalis, chlamydia, neisseria gonorrhoeae, mycoplasma, mycoplasma hominis, ureaplasma urealyticum, Mycelia, Treponema pallidum, Herpes simplex virus type 1 and type 2 and human papilloma virus type 6 and type 11.

The invention belongs to the fields of biology and medicine, and particularly relates to a nucleic acid aptamer capable of specifically recognizing beta-lactoglobulin and application of the nucleic acid aptamer. The nucleic acid aptamer has a sequence shown in SEQ ID NO.1; or a sequence which has 60% of homology or above with the sequence shown in the SEQ ID NO.1 and can specifically recognize thebeta-lactoglobulin; or a sequence which is derived from the sequence shown in the SEQ ID NO.1 and can specifically recognize the beta-lactoglobulin. The nucleic acid aptamer can specifically bind theallergen beta-lactoglobulin in cow milk and milk products, and a new tool is provided for high-sensitivity and low-cost detection of the allergen beta-lactoglobulin.

The invention relates to a fluorescence method for detecting beta-lactoglobulin based on quantum dot-nucleic acid aptamer-graphene oxide. Carboxyl modified water-soluble quantum dots are used as a fluorophore; an amino-modified aptamer is used as a recognition molecule; graphene oxide (GO) is used as a quenching agent, a novel composite nano fluorescent probe is constructed, a reactant is shot andimaged under an ultraviolet lamp, and quantitative detection data is obtained by using image J image processing software, thereby realizing high-sensitivity detection of target molecule beta-lactoglobulin.

The invention discloses a method for separating [alpha]-lactalbumin and [beta]-lactoglobulin. The present invention relates to a method for providing an alpha-lactalbumin fraction and a beta-lactoglobulin fraction from a whey material obtained from milk, the method comprising the steps of: (i) providing the whey material; (ii) contacting the whey material with a chromatographic support allowing beta-lactoglobulin to be retained by the chromatographic support; (iii) obtaining a permeate fraction from the chromatographic support comprising the alpha-lactalbumin fraction; (iv) optionally washing the chromatographic support; and (v) obtaining a retentate fraction from the chromatographic support comprising the beta-lactoglobulin fraction; wherein the whey material provided in step (i) has been depleted, or substantially depleted from at least one whey protein, such as at least 2 whey proteins, e.g. at least 3 whey proteins.

The invention relates to a method for treating hemoglobinopathy in an individual. The method comprises the following steps: (a), an evaluation step; the evaluation step comprises the process of evaluating the ability to generate the required level of gamma-globulin or fetal hemoglobin after differentiation of a first population of modified CD34 positive hematopoietic stem / progenitor cells, whereinthe first population of modified CD34 positive HSPC is derived from the individual and modified to reduce the BCL11A function; and (b), a treatment step; the treatment step comprises the process of administering a second population of modified CD34 positive HSPC to the individual; and the modified CD34 positive HSPC is derived from the individual and modified to reduce the BCL11A function. Meanwhile, the invention also relates to a method for treating hemoglobinopathy in the individual, a method of selecting an individual suffering from hemoglobinopathy for treatment with the second population of modified CD34 positive HSPC, and a method of determining whether an individual suffering from hemoglobinopathy is suitable or not suitable for treatment with the second population of modified CD34 positive HSPC derived from the individual and modified to reduce the BCL11A function.

The invention relates to a preparation method of a photoelectrochemical immunosensor for detecting dairy allergen beta-lactoglobulin, and belongs to the technical fields of functional nano materials, food analysis and photoelectrochemical biosensing. A CdWO4-TiO2 heterojunction composite material is fixed on the surface of an ITO (Indium Tin Oxide) electrode, CdS quantum dots are used for sensitization to enhance absorption of light, the CdS quantum dots are used as a connecting agent to fix an allergen beta-lactoglobulin antibody, the photocurrent response and sensitivity are effectively improved, through a layer-by-layer assembly method, by utilizing the good photoelectric activity of the CdWO4-TiO2 heterojunction sensitized by the CdS quantum dots and the specific binding between the beta-lactoglobulin and the beta-lactoglobulin antibody, the ultra-sensitive detection of the beta-lactoglobulin is realized, and the method has important significance on the analysis and detection application of the beta-lactoglobulin in dairy products.

The invention discloses a cell cryopreservation medium for dendritic cells. An effective amount of cryoprotective agents, cell stabilizers and anti-setting agents are added into RPMI-1640 culture medium and uniformly mixed to form the cell cryopreservation medium for the dendritic cells. The cryoprotective agent is dimethyl sulfoxide, and the cell stabilizer is human gamma globulin; the anti-setting agent is poly-L-lysine, and the molecular weight range of the poly-L-lysine is 30000 to 70000; and the volume percentage concentration of the dimethyl sulfoxide is 1 to 3 percent. When used for cryopreserving DCs, the cell cryopreservation medium disclosed by the invention can ensure the cryopreservation revival rate and immunocompetence of the DCs, and the cryopreservation revival rate and the immunocompetence are not significantly decreased within one year of cryopreservation; the human gamma globulin as the cell stabilizer can maintain the immunocompetence of the DCs; the poly-L-lysine as the anti-settling agent can prevent the human gamma globulin from settling to the bottom of the cell cryopreservation medium in the process of storage, and moreover, the poly-L-lysine has part of the effect of the cryoprotective agent, and can also help to maintain the immunocompetence of the DCs.

The invention discloses a sargassum thunbergii lectin and a preparation method thereof, wherein the preparation method of the sargassum thunbergii lectin is characterized by selecting sargassum thunbergii as a raw material, carrying out lyophilization, pulverization, immersion, centrifugation, ammonium sulfate fractionation, DEAE-52 ion-exchange chromatography and SephadexG-200 gel filtration chromatography, thus producing the sargassum thunbergii lectin with a molecular weight of 17 kD. The sargassum thunbergii lectin of the invention can agglutinate a wide range of cells, has agglutinative functions for erythrocytes of rabbits, dogs, sheep, crucians, chickens and humans (A, B, AB), and the like, wherein minimum concentrations of agglutination reactions with rabbit and chicken erythrocytes are 4.4mg / ml and 0.55 mg / ml respectively, and shows hemagglutinin activity for rabbit erythrocytes even after heating treatment at 100 DEG C for 30 min (the activity decreases by 75%). A sugar inhibition experiment shows that the sargassum thunbergii lectin is only inhibited by glycoproteins as bovine thyroglobulin and gamma-globulin, and the minimum inhibition concentrations are 1.25 mg.mL<-1> and 2.5 mg.mL<-1> respectively.

The present invention provides new compositions and methods useful for the treatment and potential cure of beta-globinopathies such as sickle cell disease and beta-thalassemia by inhibiting the expression and / or activity of RIOK3.